Long-term effects of cholesterol-lowering therapy

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial was our first large, long-term, multicentre trial. Outcomes are now being analysed after 16 years of follow-up of 9000 patients treated for prevention of recurrent heart disease.

The size and longevity of the LIPID study provides a rich source of data for research on the effects of lipid-lowering treatment and the relationships between patient characteristics and their risks and their subsequent cardiovascular events.

Blood samples collected over the initial phase of the trial have been analysed in the laboratories of collaborating scientists from Perth, Germany, Sweden and the United States. They are being used in a new round of investigations to determine how various biological and genetic markers are related to the risk of cardiovascular disease and to the effects of pravastatin.

Recent publications resulting from LIPID study data can be found here 

For more information contact Helen Pater, LIPID Project Manager

Study Design Graphic